Abstract
It has been established that diabetes results in a cardiomyopathy, and increasing evidence suggests that an altered substrate supply and utilization by cardiac myocytes could be the primary injury in the pathogenesis of this specific heart muscle disease. For example, in diabetes, glucose utilization is insignificant, and energy production is shifted almost exclusively towards β-oxidation of free fatty acids (FFA). FFA's are supplied to cardiac cells from two sources: lipolysis of endogenous cardiac triglyceride (TG) stores, or from exogenous sources in the blood (as free acid bound to albumin or as TG in lipoproteins). The approximate contribution of FFA from exogenous or endogenous sources towards β-oxidation in the diabetic heart is unknown. In an insulin-deficient state, adipose tissue lipolysis is enhanced, resulting in an elevated circulating FFA. In addition, hydrolysis of the augmented myocardial TG stores could also lead to high tissue FFA. Whatever the source of FFA, their increased utilization may have deleterious effects on myocardial function and includes the abnormally high oxygen requirement during FFA metabolism, the intracellular accumulation of potentially toxic intermediates of FFA, a FFA-induced inhibition of glucose oxidation, and severe morphological changes. Therapies that target these metabolic aberrations in the heart during the early stages of diabetes could potentially delay or impede the progression of more permanent sequelae that could ensue from otherwise uncontrolled derangements in cardiac metabolism.
Similar content being viewed by others
References
Palumbo PJ, Elveback CR, Conolly DC: Coronary artery disease and congestive heart failure in the diabetic: Epidemiological aspects. The Rochester Diabetes Project. In: RC Scott (ed). Clinical Cardiology and Diabetes. Futura, New York, 1981, p 13
Kannel WB, McGee DL: Diabetes and cardiovascular disease: The Framingham Study. JAMA 229: 1749–1754, 1974
Ledet B, Neubauer B, Christnesen NJ, Lundback K: Diabetic cardiopathy. Diabetologia 16: 207–209, 1979
Hamby RI, Zoneraich S, Sherman L: Diabetic cardiomyopathy. JAMA 229: 1749–1754, 1974
Regan TJ, Lyons MM, Ahmed SS: Evidence for cardiomyopathy in familial diabetes mellitus. J Clin Invest 60: 885–889, 1977
Miller TB Jr: Cardiac performance of isolated perfused hearts from alloxan diabetic rats. Am J Physiol 236: 808–812, 1979
Fein FS, Sonnenblick EH: Diabetic cardiomyopathy. Prog Cardiovasc Res 27: 255–270, 1985
Vadlamudi RVSV, Rodgers RL, McNeill JH: The effect of chronic alloxan-and streptozotocin-induced diabetes on isolated rat heart performance. Can J Physiol Pharmacol 60: 902–911, 1982
Rodrigues B, McNeill JH: The diabetic heart: Metabolic causes for the development of a cardiomyopathy. Cardiovasc Res 26: 913–992, 1992
Rodrigues B, Cam MC, McNeill JH: Myocardial substrate metabolism: Implications for diabetic cardiomyopathy. J Mol Cell Cardiol 27: 169–179, 1995
Gibbons GF: Assembly and secretion of hepatic very-low-density lipoprotein. Biochem J 268: 1–13, 1990
Rodrigues B, Grassby PF, Battell ML, Lee SYN, McNeill JH: Hypertriglyceridemia in experimental diabetes: Relationship to cardiac dysfunction. Can J Physiol Pharmacol 72: 447–455, 1994
Mamo JCL, Hirano T, Sainsbury A, Fitzgerald AK, Redgrave TG: Hypertriglyceridemia is exacerbated by slow lipolysis of triacylglycerol-rich lipoproteins in fed but not fasted streptozotocin diabetic rats. Biochim Biophys Acta 1128: 132–138, 1992
Kannel WB, McGee DL: Diabetes and cardiovascular risk factors. The Framingham Study. Circulation 59: 8–13, 1979
West KM, Ahuja MMS, Bennett PH, Czyzyk A, Mateo de Acosta O, Fuller JH, Grab B, Grabauskas V, Jarrett RJ, Kosaka K, Keen H, Krolewski AS, Miki E, Schliack V, Teuscher A, Watkins PJ, Strober JA: The role of circulating glucose and triglyceride concentrations and their interactions with other ‘risk factors’ as determinants of arterial disease in nine diabetic population samples from the WHO Multi National study. Diabetes Care 6: 361–369, 1983
Rodrigues B, Xiang H, McNeill JH: Effects of L-carnitine treatment on lipid metabolism and cardiac performance in chronically diabetic rats. Diabetes 37: 1358–1364, 1988
Rodrigues B, Goyal RK, McNeil1 JH: Effects of hydralazine on streptozotocin-induced diabetic rats: Prevention of hyperlipidemia and improvement in cardiac function. J Pharmacol ExpTher 237: 292–299, 1986
McNeill JH, Rodrigues B: Heart function in WKY diabetic rats. J Mol Cell Cardiol 28(6): A202, 1996
Denton RM, Randle PJ: Concentration of glycerides and phospholipids in rat heart and gastronemius muscles. Effects of alloxan-diabetes and perfusion. Biochem J 104: 416–422, 1967
Kenno KA, Severson DL: Lipolysis in isolated myocardial cells from diabetic rat hearts. Am J Physiol 249: 1024–1030, 1985
Chattopadhyay J, Thompson EW, Schmid HHO: Elevated levels of nonesterified fatty acids in the myocardium of alloxan diabetic rats. Lipids 25: 307–310, 1990
Eckel RH: Lipoprotein lipase. A multifunctional enzyme relevant to common metabolic diseases. N Engl J Med 320: 1060–1068, 1989
O'Brien KD, Ferguson M, Gordon D, Deeb SS, Chait A: Lipoprotein lipase is produced by cardiac myocytes rather than interstitial cells in human myocardium. Arterioscler Thromb 14: 1445–1451, 1994
Hamosh M, Hamosh P: Lipoprotein lipase: Its physiological and clinical significance. Mol Aspects Med 6: 199–289, 1983
Elkeles RS, Hambley J: The effects of fasting and streptozotocin on hepatic triglyceride lipase activity in the rat. Diabetes 26: 58–60, 1977
Veeraraghavan K, Murthy K, Bauman MD, Shipp J: Regulation of triacylglycerol lipolysis in the perfused hearts of normal and diabetic rats. Diabetes 32: 718–722, 1983
Nomura T, Hagino H, Gotoh M, Iguchi A, Sakamoto N: The effects of streptozotocin diabetes on tissue specific lipase activities in the rat. Lipids 19: 594–599, 1984
Tavangar K, Murata Y, Pedersen ME, Goers JF, Hoffman AR, Kraemer FB: Regulation of lipoprotein lipase in the diabetic rat. J Clin Invest 90: 1672–1678, 1992
O'Looney P, Maten MV, Vahouny GV: Insulin-mediated modifications of myocardial lipoprotein lipase and lipoprotein metabolism. J Biol Chem 258: 12994–13001, 1983
Braun JEA, Severson DL: Lipoprotein lipase release from cardiac myocytes is increased by decavanadate but not insulin. Am J Physiol 262: 663–670, 1992
Rodrigues B, Severson DL: Acute diabetes does not reduce heparin-releasable lipoprotein lipase activity in perfused hearts from Wistar-Kyoto rats. Can J Physiol Pharmacol 71: 657–661, 1993
Mamo JCL, Hirano T, Sainsbury A, Fitzgerald AK, Redgrave TG: Hypertriglyceridemia is exacerbated by slow lipolysis of triacylglycerol-rich lipoproteins in fed but not fasted streptozotocin diabetic rats. Biochim Biophys Acta 1128: 132–138, 1992
Rutledge JC, Goldberg IJ: Lipoprotein lipase (LpL) affects low density lipoprotein (LDL) flux through vascular tissue: Evidence that LpL increases LDL accumulation in vascular tissue. J Lipid Res 35: 1152–1160, 1994
Fernandez-Borja M, Bellido D, Vilella E, Olivecrona G, Vilaro S: Lipoprotein lipase-mediated uptake of lipoprotein in human fibroblasts: Evidence for an LDL receptor-independent internalization pathway. J Lipid Res 37: 464–481, 1996
Tsutsumi K, Inoue Y, Shina A, Murase T: Correction of hypertiglyceridemia with low high-density lipoprotein cholesterol by the novel compound NO-1886, a lipoprotein lipase promoting agent, in STZ-induced diabetic rats. Diabetes 44: 414–417, 1995
Liu K, Pierce GN: The effects of low density lipoprotein on Ca2+ transients in isolated rabbit cardiomyocytes. J Biol Chem 268: 3767–3775, 1993
DeFronzo RA, Jacot E, Jequier E, Maeder E, Wahren J, Felber JP: The effect of insulin on the disposal of intravenous glucose: Results from indirect calorimetry and hepatic and femoral venous catheterization. Diabetes 30: 1000–1007, 1981
Cushman SW, Wardzala LJ: Potential mechanism of insulin action on glucose transport in the isolated rat adipose cell. Apparent translocation of intracellular transport systems to the plasma membrane. J Biol Chem 255: 4758–4762, 1980
Karnieli E, Zarnowski MJ, Hissin PJ, Simpson IA, Salans LB, Cushman SW: Insulin-stimulated translocation of glucose transport systems in the isolated rat adipose cell. J Biol Chem 256: 4772–4777, 1981
Chen V, Ianuzzo CD, Fong BC, Spitzer JJ: The effects of acute and chronic diabetes on myocardial metabolism in rats. Diabetes 33: 1078–1084, 1984
Eckel J, Reinauer H: Insulin action on glucose transport in isolated cardiac myocytes: Signalling pathways and diabetes induced alterations. Biochem Soc Trans 18: 1135–1137, 1990
Garvey WG, Hardin D, Juhaszova M, Dominguez JH: Effects of diabetes on myocardial glucose transport system in rats: implication for diabetic cardiomyopathy. Am J Physiol 264: 837–844, 1993
Randle PJ, Hales CN, Garland PB, Newsholme EA: The glucose fatty acid cycle: Its role in insulin sensitivity and the metabolic disturbances of diabetes mellitus. Lancet 1: 785–789, 1963
Chen V, Ianuzzo CD: Dosage effect of streptozotocin on rat tissue enzyme activities and glycogen concentration. Can J Physiol Pharmacol 60: 1251–1256, 1982
Kerbey AK, Vary TC, Randle PJ: Molecular mechanisms regulating myocardial glucose oxidation. Basic Res Cardiol 80 (suppl 2): 93–96, 1985
Wieland O, Siess E, Schulze-Wethmar FH, van Funcke HG, Winton B: Active and inactive forms of pyruvate dehydrogenase in rat heart and kidney: Effects of diabetes, fasting and refeeding on pyruvate dehydrogenase interconversion. Arch Biochem Biophys 143: 593–601, 1971
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Rodrigues, B., Cam, M.C. & McNeill, J.H. Metabolic disturbances in diabetic cardiomyopathy. Mol Cell Biochem 180, 53–57 (1998). https://doi.org/10.1023/A:1006882805197
Issue Date:
DOI: https://doi.org/10.1023/A:1006882805197